Legal Representation
Attorney
Karen Kreider Gaunt
USPTO Deadlines
Next Deadline
42 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20200303)
Due Date
March 03, 2026
Grace Period Ends
September 03, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
16 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 3, 2025 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
| Mar 3, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Dec 17, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 17, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 27, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 12, 2019 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 7, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 7, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 31, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Oct 25, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 25, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 25, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 25, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 21, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 29, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 15, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Medical research; biological research, clinical research in the field of pharmaceuticals and medical research; pharmaceutical research services; research on the subject of pharmaceuticals; scientific research in the field of pharmacy; pharmaceutical research and development services; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical drug development services; conducting early evaluations in the field of new pharmaceuticals; medical laboratory services; laboratory research services relating to pharmaceuticals
First Use Anywhere:
Jun 30, 2014
First Use in Commerce:
Jun 30, 2014
Additional Information
Design Mark
The mark consists of the literal element "REDOXIS" in lowercase letters. To the left of "REDOXIS" is a stylized version of a lowercase "R" which is represented in red. The "X" in "REDOXIS" is also represented in red while the remaining letters are in black.
Color Claim
The color(s) red and black is/are claimed as a feature of the mark.
Translation
The wording "REDOXIS" has no meaning in a foreign language.
Classification
International Classes
042